Contract Testing
We are an agent for overseas CROs that perform non-clinical safety and efficacy tests necessary for the development of pharmaceuticals, pesticides, etc.
This is a long-established American laboratory with 80 years of experience.
We have a world-leading track record in efficacy and safety testing of infectious disease treatments and vaccines, including SARS-CoV-2.
We undertake contract manufacturing of cell banks for biopharmaceutical manufacturing, GMP manufacturing of virus seeds, ICH Q5A virus safety tests, and virus clearance tests. We also have extensive experience in virus denial tests using NGS.
We provide a wide range of support, from efficacy testing of pharmaceuticals and other products to toxicity testing and formulation manufacturing. In particular, we have a world-leading track record in toxicity testing using miniature pigs. We specialize in efficacy testing of CNS and rare disease models.
We are a CRO specializing in inhalation testing, equipped with cutting-edge inhalation equipment and staffed by researchers with many years of experience. We have a proven track record in inhalation testing, covering single-dose toxicity, repeated-dose toxicity, reproductive and developmental toxicity, and carcinogenicity tests.
As a CRO specializing in zebrafish, we not only conduct toxicity tests, but also create various disease models using gene modification technology and conduct efficacy tests. We also conduct screening tests for endocrine disruptors.
We are a CRO specializing in environmental risk assessment. We provide comprehensive services, from ecotoxicology testing of aquatic and terrestrial plants and animals, environmental fate testing, various metabolic testing, and chemical analysis (5 batches, etc.), to consultation and expert report creation upon request.
We are a CRO specializing in in vitro assays using human tissues. We conduct risk assessments of immunotoxicity, such as drug rash and GvHD, caused by pharmaceuticals.
We offer in vitro assays for characterizing the binding and cytotoxicity of immune-related modalities such as antibodies and CAR-T.
Using our unique humanized immune system mice (Human Immune System Mice: HiMice), we undertake efficacy and toxicity testing for drug development targeting cancer, infectious diseases, autoimmune diseases, liver diseases, etc.
With over 30 years of experience in environmental risk assessment of pharmaceuticals and pesticides, the company is one of the world's leading CROs, conducting over 700 GLP studies per year, and also has a wealth of experience in endocrine-related studies.
Infectious disease model
SARS-COV-2
Influenza A
Respiratory Syncytial Virus (RSV)
Vaccinia
Herpes Simplex Virus (HSV-1)
West Nile Virus
Zika virus, Yellow fever
Chikungunya virus
Hepatitis B virus (HBV)
Dengue virus (DENV-2 or 1)
Monkeypox
SIV, SHIV, etc.
Cancer-bearing model
Patient-Derived Xenograft (PDX): Breast cancer, lung adenocarcinoma, ovarian adenocarcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma
Cell line-derived xenograft (CDX): Lung cancer, breast cancer, colorectal cancer, ovarian cancer, prostate cancer, lymphoma, glioblastoma, myeloma, liver cancer, kidney cancer
Immune disease models:
Systemic lupus erythematosus (SLE)
Graft host disease (GvHD)
Inflammation model:
Nonalcoholic steatohepatitis (NASH)
Inflammatory bowel disease (IBD)
Hepatitis (viral)
Cytokine release syndrome (CRS)
Central Nervous System/Neurodegenerative Disease Models
Alzheimer's disease (APP/Aβ, Tau, AAV, Seeding model, Aged animals, scopolamine induction)
Parkinson's disease (α-Syn, MPTP or 6-OHDA induced, MJFF)
Niemann-Pick disease
Huntington's disease
Amyotrophic lateral sclerosis (ALS)
Gaucher disease
Alport syndrome
Mucopolysaccharidosis type IIIA (MPS IIIA)
Pompe disease
Mental illness (schizophrenia, depression, autism spectrum disorder, multiple sclerosis)